NEW YORK (GenomeWeb) – Investment bank Piper Jaffray on Thursday initiated coverage of Veracyte with an overweight rating on the firm's stock and a $21 price target.
Registering provides access to this and other free content.
Already have an account?Login Now.
An opinion piece appearing in Newsday likens familial DNA search to stop-and-frisk policies.
The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.
In Nature this week: genotypes linked to hip osteoarthritis, and more.
Startup companies are taking on personalized medicine, CNET reports.